Renal Pelvis Adenocarcinoma
There are 2 clinical trials for renal pelvis adenocarcinoma, of which 1 is open and 1 is completed or closed. Of the trials that contain renal pelvis adenocarcinoma as an inclusion criterion, 2 are phase 2 (1 open).
Durvalumab, nilotinib, and paclitaxel are the most common interventions in renal pelvis adenocarcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.